PROBE-PD
  • Sobre
  • Projeto
  • Equipe
  • Publicações
  • Parkinson
  • Contato
  • Português
    • Português
  • Home
Escolha uma Página
Genetic risk of ADHD may boost odds of Alzheimer’s in old age

Genetic risk of ADHD may boost odds of Alzheimer’s in old age

por Fernando Rigon | dez 8, 2022 | News

Having a genetic predisposition to attention-deficit/hyperactivity disorder, or ADHD, is associated with cognitive decline and may predict Alzheimer’s disease in old age, early research released Thursday suggests. Recent large studies have hinted at a link...

Endocannabinoid System Biomarkers in Alzheimer’s Disease.

por jcdadm.website | nov 17, 2022 | Publication

Ferreira PCL, Bellaver B, Povala G, Brum WS, Tissot C, Badji A, Sloan ME, Benedet AL, Rosa-Neto P, Ashton NJ, Pascoal TA, Leuzy A, Zimmer ER. Cannabis Cannabinoid Res. 2022 Nov 17. doi: 10.1089/can.2022.0151. Online ahead of print.

The association of age-related and off-target retention with longitudinal quantification of [18F]MK6240 tau-PET in target regions.

por jcdadm.website | nov 17, 2022 | Publication

Tissot C, Servaes S, Lussier FZ, Ferrari-Souza JP, Therriault J, Ferreira PCL, Bezgin G, Bellaver B, Teixeira Leffa D, Mathotaarachchi SS, Chamoun M, Stevenson J, Rahmouni N, Kang MS, Pallen V, Poltronetti NM, Wang YT, Fernandez-Arias J, Benedet AL, Zimmer ER, Soucy...

Subjective cognitive decline in Brazil: Prevalence and association with dementia modifiable risk factors in a population-based study.

por jcdadm.website | nov 14, 2022 | Publication

Borelli WV, Zimmer ER, Bieger A, Coelho B, Pascoal TA, Chaves MLF, Amariglio R, Castilhos RM. Alzheimers Dement (Amst). 2022 Nov 14;14(1):e12368. doi: 10.1002/dad2.12368. eCollection 2022.
Transcranial Direct Current Stimulation vs Sham for the Treatment of Inattention in Adults

Transcranial Direct Current Stimulation vs Sham for the Treatment of Inattention in Adults

por Fernando Rigon | out 12, 2022 | News

Attention-deficit/hyperactivity disorder (ADHD) is a neurodevelopmental condition that affects 2.5% of adults worldwide. Pharmacotherapy is the recommended initial treatment for most adults, but patient adherence can be low due to adverse effects and other concerns....

Author Correction: [11C]Martinostat PET analysis reveals reduced HDAC I availability in Alzheimer’s disease.

por jcdadm.website | out 3, 2022 | Publication

Pascoal TA, Chamoun M, Lax E, Wey HY, Shin M, Ng KP, Kang MS, Mathotaarachchi S, Benedet AL, Therriault J, Lussier FZ, Schroeder FA, DuBois JM, Hightower BG, Gilbert TM, Zürcher NR, Wang C, Hopewell R, Chakravarty M, Savard M, Thomas E, Mohaddes S, Farzin S, Salaciak...
Molecular Psychiatry: Astrocyte Biomarker Signatures of Amyloid-β and Tau Pathologies in Alzheimer’s Disease

Molecular Psychiatry: Astrocyte Biomarker Signatures of Amyloid-β and Tau Pathologies in Alzheimer’s Disease

por Fernando Rigon | set 29, 2022 | News

In Alzheimer’s disease, reactive astrocytes can play an important role in the pathophysiology of the disease. Amyloid-β and tau tangles—the two main pathological hallmarks of Alzheimer’s disease—are associated with astrocyte reactivity. However, knowledge about...
Pitt Psychiatry Awarded $33.5M NIH Program Project Grant Focused on the Pathological and Clinical Progression of AD

Pitt Psychiatry Awarded $33.5M NIH Program Project Grant Focused on the Pathological and Clinical Progression of AD

por Fernando Rigon | set 14, 2022 | News

The National Institute on Aging (NIA) has awarded the University of Pittsburgh Department of Psychiatry a Program Project Grant (PPG) renewal for “The role of astrogliosis in aging and the pathological and clinical progression of Alzheimer’s disease.” The...

Staging of Alzheimer’s disease: past, present, and future perspectives.

por jcdadm.website | set 1, 2022 | Publication

Therriault J, Zimmer ER, Benedet AL, Pascoal TA, Gauthier S, Rosa-Neto P. Trends Mol Med. 2022 Sep;28(9):726-741. doi: 10.1016/j.molmed.2022.05.008. Epub 2022 Jun 15.

Comment on “Microglial activation states drive glucose uptake and FDG-PET alterations in neurodegenerative diseases”.

por jcdadm.website | ago 24, 2022 | Publication

Zimmer ER, Pascoal TA, Rosa-Neto P, Nordberg A, Pellerin L. Sci Transl Med. 2022 Aug 24;14(659):eabm8302. doi: 10.1126/scitranslmed.abm8302. Epub 2022 Aug 24.
Página 1 de 1012345...10...»Last »

Recent Posts

  • Genetic risk of ADHD may boost odds of Alzheimer’s in old age
  • Transcranial Direct Current Stimulation vs Sham for the Treatment of Inattention in Adults
  • Molecular Psychiatry: Astrocyte Biomarker Signatures of Amyloid-β and Tau Pathologies in Alzheimer’s Disease
  • Pitt Psychiatry Awarded $33.5M NIH Program Project Grant Focused on the Pathological and Clinical Progression of AD
  • Study Challenges Dogma Behind Alzheimer’s Disease Drug Trials

Website by